CD47 and neoplasm: Because the potent role of CD47/SIRP-alpha signaling in suppression of macrophage phagocytosis, blocking the CD47/SIRP-alpha interaction between macrophages and tumor cells has become a promising approach in cancer immunotherapy (10–12).